Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 21, Issue 9, 1998, Pages 580-588

  Carmina, E ^a   Lobo, R A ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Adrenal hyperandrogenism; Non classic congenital hyperplasia (NC CAH); PCOS

Indexed keywords

ANDROGEN; INSULIN;

ADRENAL GLAND; ANDROGEN RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FEMALE; HUMAN; HYPERANDROGENISM; NONHUMAN; OVARY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY;

EID: 0031784061     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350783     Document Type: Article

References (56)

1. Lobo R.A. The role of the adrenal in the Polycystic Ovary Syndrome. Semin. Reprod. Endocrinol. 2: 251, 1984.
2. Lobo R.A.,Carmina E. Polycystic Ovary Syndrome. In: Lobo R.A., Mishell D.R. Jr, Paulson R., Shoupe D. (Eds.), Mishell's Textbook of Infertility, Contraception and Reproductive Endocrinology. Blackwell Pub., Oxford, 1997, p. 362.
3. Gallagher T.F., Kappos A., Hallman L., Lipsett M.B., Pearson O.H., West C.D. Adrenocortical hyperfunction in idiopathic hirsutism and the Stein-Leventhal Syndrome. J. Clin. Invest. 57: 794, 1958.
4. Gemzell C.A., Tillinger K.G., Westman A. A clinical study of ovarian pathology in the urinary excretion of 17-ketosteroids. Acta Endocrinol. 30: 387, 1959.
5. Jones G.E.S., Howard J.E., Langford H. The use of cortisone in follicular phase disturbances. Fertil. Steril. 4: 49, 1953.
6. Lobo R.A., Paul W., March C.M., Granger L, Kletzky O.A. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet. Gynecol. 60: 497, 1982.
7. Yen S.S.C., Chaney C., Judd H.L. Functional aberrations of the hypothalamic-pituitary system in polycystic ovary syndrome. A consideration of the pathogenesis. In: James V.H., Serio M., Giusti G. (Eds.), The endocrine function of the human ovary. Academic Press, New York, 1976, p. 373.
8. Yen S.S.C. Chronic anovulation caused by peripheral endocrine disorders. In: Yen S.S.C., Jaffe R.B. (Eds.), Reproductive Endocrinology. Saunders Co., Philadelphia, 1991, p. 576.
9. Chang R.J., Mandel F.P., Lu J.K.H., Judd H.L. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 54: 490, 1982.
10. Ehrmann D.A., Barnes R.B., Rosenfield R.L. Polycystic ovary syndrome as a functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr. Rev. 16: 322, 1995.
11. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41: 1257, 1992.
12. Gilling-Smith C., Willis D.S., Beard R.W., Franks S. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 79: 1158, 1994.
13. Carmina E., Koyama T., Chang L., Stanczyk F.Z., Lobo R.A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am. J. Obstet. Gynecol. 167: 1807, 1992.
14. Carmina E. Prevalence of adrenal androgen excess in PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 385.
15. Wild R.A., Umstot E.S., Andersen R.N., Ranney G.B., Givens J.R. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am. J. Obstet. Gynecol. 146: 602, 1988.
16. Hoffman D.L., Klove K., Lobo R.A. The prevalence and significance of elevated dehydroepiandrosterone sulfate in anovulatory women. Fertil. Steril. 42: 76, 1984.
17. Carmina E., Rosato F., Janni A. Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients. J. Endocrinol. Invest. 9: 5, 1986.
18. Carmina E., Stanczyk F.Z., Chang L., Miles R.A., Lobo R.A. The ratio of androstenedione: 11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. Fertil. Steril. 58: 148, 1992.
19. Carmina E., Gonzalez F., Chang L., Lobo R.A. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet. Gynecol. 85: 971, 1995.
20. Moltz L., Schwartz U., Sorensen R., Pickhartz H., Hammerstein J. Ovarian and adrenal vein steroids in patients with nonneoplastic hyperandrogenism: selective catheterization findings. Fertil. Steril. 42: 69, 1984.
21. Mahesh V.B. Animal models for the study of PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 359.
22. Ward R.C., Costoff A., Mahesh V.B. The induction of polycystic ovaries in mature cycling rats by the administration of dehydroepiandrosterone Biol. Reprod. 18: 614, 1978.
23. Abbott D.H., Dumesic D.A., Eisner J.R., Kenmitz J.W., Goy R.W. The prenatally androgenized female rhesus monkey as a model for PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 369.
24. Faiman C., Reyes F.I., Dent D.W., Fuller G.B., Hobson W.C., Thiliveris J.A. Effects of long term testosterone exposure on ovarian function and morphology in the rhesus monkey. Anat. Rec. 222: 245, 1988.
25. Kenmitz J.W., Goy R.W., Flitsch T.J., Lohmiller J.J., Robinson J.A. Obesity in male and female rhesus monkeys: fat distribution, glucoregulation and serum androgen levels. J. Clin. Endocrinol. Metab. 69: 287, 1989.
26. Morel Y., Miller W.L. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv. Hum. Genet. 20: 1, 1991.
27. Carmina E. Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia. Reprod. Med. Rev. 4: 179, 1995.
28. Lobo R.A., Goebelsmann U. Evidence for reduced 3-beta-ol-hydroxysteroid-dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 53: 394, 1981.
29. Zerah M., Rheaume E., Mani P.,Schram P., Simard J., Labrie F., New M.I. No evidence of mutations in the genes for type I and type II 3β-hydroxysteroid dehydrogenase (3β-HSD) in nonclassical 3β-HSD deficiency. J. Clin. Endocrinol. Metab. 79: 1811, 1994.
30. Chang Y.T., Zhang L., Alkaddour H.S., Mason H.I., Lin K., Xang X., Garibaldi L.R., Bourdony C.J., Dolan L.M., Donaldson D.L., Pang S. Absence of molecular defects in the type II 3I-hydroxysteroid-dehydrogenase (3β-HSD) gene in premature pubarche and hirsute female patients with moderately decreased adrenal 3β-HSD activity. Pediatr. Res. 37: 820, 1995.
31. Levin J.H., Carmina E., Lobo R.A. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult onset congenital adrenal hyperplasia? Fertil. Steril. 56: 635, 1991.
32. Carmina E., Lobo R.A. Ovarian suppression reduces clinical and endocrine expression of late onset congenital adrenal hyperplasia due to a 21-hydroxylase deficiency. Fertil. Steril. 62: 738, 1994.
33. Carmina E. The role of extra-adrenal factors in adrenal androgen excess: in vivo studies. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 425.
34. Gonzalez F., Chang L., Horab T., Lobo R.A. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Fertil. Steril. 66: 354, 1996.
35. Fruzzetti F., De Lorenzo D., Ricci C., Teti G. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome. Fertil. Steril. 63: 734, 1995.
36. Casson P.R., Kristiansen S.B., Umstot E., Carson S.A., Buster J.A. Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Fertil. Steril. 65: 950, 1996.
37. Casson P.R., Buster J.E., Hornsby P.J. The role of extra-adrenal factors in adrenal androgen excess: in vitro studies. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 415.
38. Gonzalez F. Adrenal involvement in Polycystic Ovary Syndrome. Semin. Reprod. Endocrinol. 15: 137, 1997.
39. Azziz R. The adrenal connection. In: Adashi E.Y., Rock J.A., Rosenwaks Z. (Eds.), Reproductive Endocrinology, Surgery and Technology. Lippincott-Raven Pub., Philadelphia, 1996, p. 1162.
40. Ditkoff E.C., Fruzzetti F., Chang L., Stanczyk F.Z., Lobo R.A. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80: 603, 1995.
41. Carmina E., Gonzalez F., Vidali A., Stanczyk F.Z., Ferin M., Lobo R.A. The contribution of estrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Hum. Reprod. 1998 (in press).
42. Nestler J.E., Usiskin K.S., Barlascini C.O., Welty D.F., Clore J.N., Blackard W.G. Suppression of serum dehydroepiandrosterone sulfate by insulin: an evaluation of possible mechanisms. J. Clin. Endocrinol. Metab. 69: 1040, 1989.
43. Beer N.A., Jakubowicz D.J., Beer R.M., Nestler J.E. Disparate effects of insulin induction by diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J. Clin. Endocrinol. Metab. 80: 700, 1995.
44. Nestler J.E., Kalwash Z. Sex specific action of insulin increases the metabolic clearance rate of dehydroepiandrosterone in humans. J. Clin. Invest. 94: 1484, 1994.
45. Moghetti P., Castello R., Negri C., Tosi F., Spiazzi G.G., Brun E., Balducci R., Toscano V., Muggeo M. Insulin infusion amplifies 17α-hydroxycorticoid intermediate response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17,20-lyase activity. J. Clin. Endocrinol. Metab. 81: 881, 1996.
46. Lanzone A., Fulghesu A.M., Guido M., Fortini A., Caruso A., Mancuso S. Differential androgen response to adrenocorticotropin hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. Fertil. Steril. 58: 296, 1992.
47. Rosenfield R.L. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J. Clin. Endocrinol. Metab. 81: 878, 1996.
48. th Ann. Meet. Am. Fert. Soc., San Antonio, USA, 1994, abs P154.
49. Dunaif A., Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J. Clin. Invest. 83: 23, 1989.
50. Azziz R., Bradley E.L. Jr, Potter H.D., Parker R.C. Jr, Boots L.R. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin (1-24) stimulation in hyperandrogenic women. Am. J. Obstet. Gynecol. 172: 1251, 1995.
51. Nestler J.E., Barlascini C.O., Matt D.W. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68: 1027, 1989.
52. Holte J., Bergh T., Gennarelli G., Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotropins and sex steroid hormones in premenopausal women. Clin. Endocrinol. 41: 473, 1994.
53. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin sensitizing troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81: 3299, 1996.
54. Carmina E., Lobo R.A. Pituitary adrenal responses to ovine corticotropin-releasing hormone in polycystic ovary syndrome and other hyperandrogenic patients. Gynecol. Endocrinol. 4: 225, 1990.
55. Azziz R. Abnormalities of adrenocortical steroidogenesis in PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, 1997, p. 403.
56. Azziz R., Bradley E.L. Jr, Potter H.D., Boots L. Adrenocortical hyperactivity and androgen excess in hyperandrogenism: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J. Clin. Endocrinol. Metab. 80: 400, 1995.